Faricimab Provides Similar nAMD, DME Outcomes at Significantly Fewer Injections
A systematic review and meta-analysis suggests the dual pathway-targeting faricimab provides some greater benefit in outcomes like CST at fewer injections and without compromise of safety to anti-VEGF monotherapies.